Dear Editor,
In two recent JCMM papers dealing with the staining of various human tissue antigens, divergent approaches for blocking endogenous peroxidase activity were reported. As such, Gray et al.[1] inhibited this intrinsic enzyme with a 0.9% hydrogen peroxide (H2O2) solution whereas Ranieri et al.[2] performed the blockade with a 3% H2O2 solution. This arbitrariness has prompted our present letter.
Immunohistochemistry (IHC) applied to formalin-fixed, paraffin-embedded tissue samples is governed by standard operating procedures like any other methodology in biomedicine. One important milestone in IHC standardization has been the revelation of endogenous biotin as a confounding factor along with measures to minimize its contribution to causing staining errors [3–5]. However, IHC pitfalls can also have other origins such as the insufficient quenching of endogenous peroxidases whenever using peroxidase-based detection methods. Despite the existence of expert manuals according to which these enzymes should be inhibited by applying a solution containing 3% H2O2[6] and studies abiding by this recommendation [2, 5, 7–9], some research groups still publish staining approaches in which blockade has erroneously been performed with less concentrated H2O2 solutions, e.g. by means of a 0.9%[1] or even 0.3%[10] solution. In this context, it was already shown that, for instance, when endogenous peroxidases were blocked by means of a 0.3% H2O2 solution a breast carcinoma was (falsely) positive for a particular protein, yet when blockade was performed by employing a 3% H2O2 solution, the same specimen stained negatively for that antigen [9]. It should be emphasized that all other conditions including primary antibody concentrations were identical in the two experimental arms at a given incubation temperature [9].
Therefore, the purpose of this note is to alert investigators to henceforth implement established techniques to avoid this mistake in order to prevent the emergence of staining artifacts associated with falsely positive IHC results and consequently augment the comparability of data generated in different laboratories on the same subject of interest. Given the increasing importance of proteomics and (intracellular) protein biomarkers for the diagnosis of human disease, appropriate countermeasures to avert this immunohistochemical pitfall should have particular relevance.
References
- 1.Gray SE, Kay E, Leader M, Mabruk M. Analysis of p16 expression and allelic imbalance/loss of heterozygosity of 9p21 in cutaneous squamous cell carcinomas. J Cell Mol Med. 2006;10:778–88. doi: 10.1111/j.1582-4934.2006.tb00437.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Ranieri G, Grammatica L, Patruno R, Zito AF, Valerio P, Iacobellis S, Gadaleta C, Gasparini G, Ribatti D. A possible role of thymidine phosphorylase expression and 5- fluorouracil increased sensitivity in oropharyngeal cancer patients. J Cell Mol Med. 2007;11:362–68. doi: 10.1111/j.1582-4934.2007.00007.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Bussolati G, Gugliotta P, Volante M, Pace M, Papotti M. Retrieved endogenous biotin: a novel marker and a potential pitfall in diagnostic immunohistochemistry. Histopathology. 1997;31:400–7. doi: 10.1046/j.1365-2559.1997.3020895.x. [DOI] [PubMed] [Google Scholar]
- 4.Iezzoni JC, Mills SE, Pelkey TJ, Stoler MH. Inhibin is not an immunohistochemical marker for hepatocellular carcinoma. An example of the potential pitfall in diagnostic immunohistochemistry caused by endogenous biotin. Am J Clin Pathol. 1999;111:229–34. doi: 10.1093/ajcp/111.2.229. [DOI] [PubMed] [Google Scholar]
- 5.Kim SH, Jung KC, Shin YK, Lee KM, Park YS, Choi YL, Oh KI, Kim MK, Chung DH, Song HG, Park SH. The enhanced reactivity of endogenous biotin-like molecules by antigen retrieval procedures and signal amplification with tyramine. Histochem J. 2002;34:97–103. doi: 10.1023/a:1020954611464. [DOI] [PubMed] [Google Scholar]
- 6.Boenisch T. Handbook of immunochemical staining methods. 3. Carpinteria, CA, USA: Dako Cytomation Corp; 2003. [Google Scholar]
- 7.Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, Schellenberg GD, Jin L-W, Kovacina KS, Craft S. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimers disease is associated with the apolipoprotein E-e4 allele. Am J Pathol. 2003;162:313–9. doi: 10.1016/s0002-9440(10)63822-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Radulescu RT, Hufnagel C, Luppa P, Hellebrand H, Kuo W-L, Rosner MR, Harbeck N, Giersig C, Meindl A, Schmitt M, Weirich G. Immunohistochemical demonstration of the zinc metalloprotease insulin-degrading enzyme in normal and malignant human breast: correlation with tissue insulin levels. Int J Oncol. 2007;30:73–80. [PubMed] [Google Scholar]
- 9.Radulescu RT, Jahn A, Hellmann D, Weirich G. Immunohistochemical pitfalls in the demonstration of insulin-degrading enzyme in normal and neoplastic human tissues. arXiv. 2007 0705. 0374v1 [q-bio.TO] [Google Scholar]
- 10.Uhlén M, Björling E, Agaton C, Szigyarto CA, Amini B, Andersen E, Andersson AC, Angelidou P, Asplund A, Asplund C, Berglund L, Bergström K, Brumer H, Cerjan D, Ekström M, Elobeid A, Eriksson C, Fagerberg L, Falk R, Fall J, Forsberg M, Björklund MG, Gumbel K, Halimi A, Hallin I, Hamsten C, Hansson M, Hedhammar M, Hercules G, Kampf C, Larsson K, Lindskog M, Lodewyckx W, Lund J, Lundeberg J, Magnusson K, Malm E, Nilsson P, Odling J, Oksvold P, Olsson I, Oster E, Ottosson J, Paavilainen L, Persson A, Rimini R, Rockberg J, Runeson M, Sivertsson A, Sköllermo A, Steen J, Stenvall M, Sterky F, Strömberg S, Sundberg M, Tegel H, Tourle S, Wahlund E, Waldén A, Wan J, Wernérus H, Westberg J, Wester K, Wrethagen U, Xu LL, Hober S, Pontén F. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics. 2005;4:1920–32. doi: 10.1074/mcp.M500279-MCP200. [DOI] [PubMed] [Google Scholar]
